Sionna Therapeutics (SION) vs Sol-Gel Technologies (SLGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Sol-Gel Technologies (SLGL) has outperformed Sionna Therapeutics (SION) over the past year, gaining 78.9% versus a loss of 82.8%. Sol-Gel Technologies is the larger company by market cap ($230.3 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SION | SLGL |
|---|---|---|
| Share price | $4.90 | $70.34 |
| Market cap | $221.24M | $230.29M |
| 1-day change | +1.66% | -2.23% |
| YTD return | -88.09% | +66.92% |
| 1-year return | -82.81% | +78.89% |
| 5-year return | — | -24.57% |
| EPS (TTM) | $-2.16 | $-5.61 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $54.97 | $97.97 |
| 52-week low | $4.01 | $28.81 |
| Distance from 52-week high | -91.09% | -28.20% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +328.57% | +116.80% |
| Average volume | 2.19M | 55.55K |
| Shares outstanding | 45.15M | 3.27M |
| Employees | 59 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLGL has outperformed SION by 161.7 percentage points over the past year.
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
About Sol-Gel Technologies
SLGL stock →Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
SION vs SLGL FAQ
Which is bigger, Sionna Therapeutics or Sol-Gel Technologies?
Sol-Gel Technologies (SLGL) is larger, with a market capitalization of $230.29M compared with $221.24M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, SION or SLGL?
SLGL returned +78.89% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Sionna Therapeutics and Sol-Gel Technologies in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.